EU Merger Regulation: Concentration Control and the SIEC Test

Introduction

The European Union Merger Regulation (EUMR), formally Council Regulation (EC) No 139/2004, establishes a mandatory ex ante control regime for concentrations with a Community dimension. The EUMR confers exclusive jurisdiction on the European Commission to assess large-scale mergers, acquisitions, and joint ventures, subject to review by the General Court and the Court of Justice of the European Union (CJEU). The Regulation reflects a fundamental policy choice: concentrations that risk significantly impeding effective competition in the internal market must be identified and remedied before implementation.

Jurisdiction and Community Dimension

A concentration arises where a change of control on a lasting basis results from the merger of two or more previously independent undertakings, the acquisition of direct or indirect sole or joint control over an undertaking, or the creation of a full-function joint venture. The jurisdictional threshold turns on “Community dimension,” defined by turnover thresholds in Article 1 EUMR. A concentration has a Community dimension where: (a) combined aggregate worldwide turnover exceeds €5,000 million; and (b) aggregate EU-wide turnover of at least two undertakings exceeds €250 million, unless each undertaking achieves more than two-thirds of its EU turnover within one and the same Member State.

Where the basic thresholds are not met, a concentration may still be notifiable under Article 1(2) if it meets lower thresholds (€2,500 million worldwide, €100 million in at least three Member States per each of at least two undertakings). The referral mechanism under Article 4(4) and Article 9 operates as a flexible corrective: parties may request referral to a Member State authority before notification, and Member States may request referral of concentrations that threaten to significantly affect competition in a distinct market within their territory.

The SIEC Test

Article 2(2)–(3) EUMR establishes the central substantive test: whether a concentration would “significantly impede effective competition in the common market or a substantial part of it, in particular as a result of the creation or strengthening of a dominant position.” The SIEC test, introduced by the 2004 reform, replaced the earlier dominance-based test and extended the Commission’s reach to non-collusive oligopolistic scenarios where coordinated effects are absent but unilateral effects nonetheless harm competition.

The SIEC test operates in two principal dimensions. Coordinated effects arise where the concentration renders the market more conducive to tacit coordination — parallel behaviour without explicit agreement — by increasing transparency, reducing the number of competitors, or aligning incentives. Unilateral (non-coordinated) effects occur where the merged entity can profitably increase prices or reduce output without coordination, particularly in differentiated markets where the merging parties are close competitors. The Commission’s Horizontal Merger Guidelines (2004) and Non-Horizontal Merger Guidelines (2008) provide the analytical framework, incorporating market shares, concentration levels (Herfindahl-Hirschman Index), entry barriers, countervailing buyer power, and efficiencies.

Phase I and Phase II Procedure

The EUMR establishes a bifurcated review timeline. Phase I lasts 25 working days from notification, during which the Commission conducts a preliminary assessment. If no serious doubts arise, the Commission issues a clearance decision, either unconditionally or subject to commitments. Where the Commission identifies serious doubts, it opens Phase II proceedings, which last 90 working days (extendable by 20 working days with the parties’ agreement or by 15 working days where remedies are offered).

During Phase II, the Commission conducts an in-depth investigation, issuing Requests for Information, holding oral hearings, and consulting with Member State competition authorities through the Advisory Committee on Concentrations. The Commission may adopt: (a) a clearance decision, unconditional or conditional; (b) a prohibition decision; or (c) in exceptional circumstances, a decision restoring effective competition where a concentration has already been implemented.

Commitments and Remedies

Where a concentration raises competitive concerns, the parties may offer commitments to render the transaction compatible with the internal market. Structural commitments — particularly divestitures — are preferred, as they maintain market structure rather than requiring ongoing behavioural monitoring. The Commission’s Notice on Remedies (2008) requires that commitments be complete and effective within a fixed timeframe, typically requiring a “suitable purchaser” approved by the Commission. Behavioural commitments, such as access commitments or non-discrimination obligations, are accepted only where structural divestiture is impossible or disproportionate.

The crown jewel mechanism addresses the risk that the initially proposed divestiture assets prove unattractive: parties must commit to divesting additional assets if the primary package fails to attract a suitable purchaser. Upfront buyer and fix-it-first requirements ensure that the purchaser is identified and approved before completion.

Landmark Cases

GE/Honeywell (2001) remains the most controversial prohibition decision. The Commission blocked the merger on conglomerate effects grounds, finding that GE’s financial strength and Honeywell’s product portfolio would create a dominant position in aerospace markets through bundling and foreclosure strategies. The European Commission’s approach diverged sharply from the US Department of Justice’s clearance, highlighting transatlantic divergence in merger control philosophy.

Ryanair/Aer Lingus (2007, prohibition; upheld on appeal 2010) illustrated the application of the SIEC test to unilateral effects in oligopolistic markets. The Commission found that 44 overlapping routes and high entry barriers would enable the merged entity to increase fares unilaterally. Ryanair’s subsequent minority stake acquisition was also challenged under Article 8(4) EUMR in 2013.

Dow/DuPont (2017, conditional clearance) imposed divestiture of DuPont’s pesticide research and development pipeline and Dow’s petrochemical assets — the largest remedy package in EUMR history. The Commission required a “natural person” overseeing compliance with the R&D divestiture, demonstrating increasing sophistication in remedy design.

The Digital Shift and the EUMR

The digital economy poses novel challenges for the SIEC test. Killer acquisitions — where dominant platforms acquire small innovative firms — may escape notification where the target’s turnover falls below jurisdictional thresholds. The Commission’s 2021 Guidance on the application of Article 22 EUMR encourages Member States to refer transactions that do not meet national thresholds to the Commission, targeting the “transactions gap” in digital markets. The Illumina/GRAIL case (2022) tested this approach; the General Court annulled the Commission’s jurisdictional decision, creating ongoing legal uncertainty that the revised thresholds in the 2024 reform package seek to address.